Schultz Shoots Back At Maisel In NEJM, Explains Handling Of Fidelis Recall
In a letter in the July 3 New England Journal of Medicine, CDRH Director Dan Schultz defends FDA's approval of some devices based only on bench testing data
In a letter in the July 3 New England Journal of Medicine, CDRH Director Dan Schultz defends FDA's approval of some devices based only on bench testing data